Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Best Practice & Research. Clinical Haematology|September 20, 2011
Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamideAshley T Munchel, Yvette L Kasamon, Ephraim J Fuchs
American Journal of Hematology|March 29, 2002
EBV-associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiencyYvette L Kasamon, Thanh N Nguyen, Jennifer A Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell LymphomaPoornima Sharma, Yvette L Kasamon, Xue Lin, et al.
The Oncologist|April 26, 2017
FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin LymphomaYvette L Kasamon, R Angelo de Claro, Yaping Wang, et al.
Pediatric Reports|November 5, 2011
Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamideAshley Munchel, Chimen Kesserwan, Heather J Symons, et al.
Molecular Imaging and Biology|November 1, 2016
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin LymphomaHeather Jacene, John Crandall, Yvette L Kasamon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2019
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary SyndromeYvette L Kasamon, Haiyan Chen, R Angelo de Claro, et al.
The Oncologist|April 11, 2022
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular LymphomaNajat Bouchkouj, Megan Zimmerman, Yvette L Kasamon, et al.
The Oncologist|March 28, 2019
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell LymphomaNicholas C Richardson, Yvette L Kasamon, Haiyan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2024
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell LymphomaMona Elmacken, Helkha Peredo-Pinto, Cong Wang, et al.
Pageof 6